Critical care services and the H1N1 (2009) influenza epidemic in Australia and New Zealand in 2010: the impact of the second winter epidemic by 
RESEARCH Open Access
Critical care services and the H1N1 (2009)
influenza epidemic in Australia and New Zealand
in 2010: the impact of the second winter
epidemic
The ANZIC Influenza Investigators
Abstract
Introduction: During the first winter of exposure, the H1N1 2009 influenza virus placed considerable strain on
intensive care unit (ICU) services in Australia and New Zealand (ANZ). We assessed the impact of the H1N1 2009
influenza virus on ICU services during the second (2010) winter, following the implementation of vaccination.
Methods: A prospective, cohort study was conducted in all ANZ ICUs during the southern hemisphere winter of
2010. Data on demographic and clinical characteristics, including vaccination status and outcomes, were collected.
The characteristics of patients admitted during the 2010 and 2009 seasons were compared.
Results: From 1 June to 15 October 2010, there were 315 patients with confirmed influenza A, of whom 283
patients (90%) had H1N1 2009 (10.6 cases per million inhabitants; 95% confidence interval (CI), 9.4 to 11.9) which
was an observed incidence of 33% of that in 2009 (P < 0.001). The maximum daily ICU occupancy was 2.4 beds
(95% CI, 1.8 to 3) per million inhabitants in 2010 compared with 7.5 (95% CI, 6.5 to 8.6) in 2009, (P < 0.001). The
onset of the epidemic in 2010 was delayed by five weeks compared with 2009. The clinical characteristics were
similar in 2010 and 2009 with no difference in the age distribution, proportion of patients treated with mechanical
ventilation, duration of ICU admission, or hospital mortality. Unlike 2009 the incidence of critical illness was
significantly greater in New Zealand (18.8 cases per million inhabitants compared with 9 in Australia, P < 0.001). Of
170 patients with known vaccination status, 26 (15.3%) had been vaccinated against H1N1 2009.
Conclusions: During the 2010 ANZ winter, the impact of H1N1 2009 on ICU services was still appreciable in
Australia and substantial in New Zealand. Vaccination failure occurred.
Introduction
Influenza A H1N1 2009 emerged in Mexico in early
2009 and spread rapidly causing a pandemic. The
World Health Organization (WHO) declared a phase 6
influenza pandemic on 11 June 2009 and declared it to
be over on 10 August 2010 [1]. The first wave of the
H1N1 2009 outbreak was notable for the number of
fatal cases among young people and atypical risk factors
for developing severe diseases. Since 19 April 2009,
WHO had reported over 491,766 laboratory-confirmed
cases of H1N1 2009 and 18,449 related deaths [1].
People in Australia and New Zealand (ANZ) were sig-
nificantly affected by the virus, with a total of 43,700
confirmed cases in Australia as of October 2010, with
6,064 cases occurring between 1 January and 15 October
2010 [2]. We have reported previously the serious
impact of the virus on the provision of critical care ser-
vices in 2009 [3]. In order to rapidly inform health pro-
fessionals in the Northern Hemisphere this study
censored new incident cases before the end of the influ-
enza season. In 2010, the deployment of vaccination and
the acquisition of natural immunity against H1N1 2009
were expected to decrease the burden of disease due to
influenza [4]. Australia and New Zealand were among
the first countries to experience a second influenza sea-
son with H1N1 2009 following widespread deployment
of vaccination.
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care unit (ICU) admissions, demographic and clinical
characteristics (including vaccination status) and out-
come of all patients with laboratory confirmed H1N1
2009 admitted to ICUs in ANZ during the second win-
ter (2010) of this influenza epidemic. We compare these
characteristics with those of patients admitted to ICU
during the corresponding period of 2009.
Material and methods
We performed a multicentre study in 187 ICUs in ANZ
comprising all adult, paediatric and combined adult and
paediatric ICUs [5]. These ICUs had a total of 1,821
beds, of which 1,487 were equipped for mechanical ven-
tilation. Each centre or region obtained Ethics Commit-
tee approval and the requirement for individual subject
informed consent was waived at all sites. We report our
findings according to STROBE guidelines for observa-
tional studies [6].
Between 1 June and 15 October, in both 2009 and
2010, we screened for patients admitted to ICU with
confirmed influenza A. Influenza A was confirmed by
reverse transcriptase polymerase chain reaction (RT-
PCR), antigen detection, or serology. H1N1 2009 and
seasonal subtypes, H1N1 and H3N2, were determined
by RT-PCR or specific serology. The laboratories were
accredited by the National Association of Testing
Authorities in Australia or by International Accredita-
tion New Zealand. Population data for Australia and
New Zealand were obtained from Australian Bureau of
Statistics [7] and Statistics New Zealand [8] for 2009
and 2010.
We collected patient-specific data as described pre-
viously [3], although vaccination status against H1N1
2009 virus was collected only during 2010. We divided
patients into the age groups used in a previous report
[9]. We calculated the duration of ICU and hospital stay
and ICU occupancy rates for Australia and New Zeal-
and. We recorded patient outcomes at ICU and hospital
discharge status or as still in hospital or in ICU as of 15
October 2010 for patients admitted in 2010 and as of 23
November 2009 for patients admitted in 2009. Finally,
we obtained data on vaccination in both countries.
Data management and statistical methods
We collected data using electronic case report forms.
The study-coordinating centre was the Australian and
New Zealand Intensive Care-Research Centre, Monash
University, Melbourne, Australia [10]. H1N1 2009 infec-
tion is subject to mandatory reporting in both Australia
and New Zealand and wherever possible diagnoses were
confirmed with the relevant public health authorities. In
addition, to confirm the completeness of case ascertain-
ment, we contacted all ICUs that had no reported cases
at the end of each study period. Cases transferred
between ICUs were counted as a single ICU case. We
made no assumptions for missing data and all propor-
tions were calculated as percentages of available data.
We performed statistical analysis using SAS version
9.1 (SAS Institute Inc., Cary, NC, USA). We calculated
descriptive statistics for all study variables. We report
continuous variables as medians with interquartile range
(IQR) and categorical variables as percentages with 95%
confidence interval (95% CI) where appropriate. We
estimated age-based population admission rates [7,11].
We compared binomial variables of the second winter
(2010) with those of the first winter (2009) using Chi-
square tests for equal proportion or Fisher’s Exact test
where numbers were small. Comparisons between con-
tinuous variables were made using Wilcoxon rank sum
test. A two-sided P-value of < 0.05 was considered to be
statistically significant.
Results
During the study period, from 1 June until 15 October
2010, 315 patients with confirmed influenza A were
admitted to an ICU, compared with 1,113 patients dur-
ing the same corresponding period in 2009. The predo-
minant sub-type was H1N1 2009 in both years (90% in
2010 versus 83% in 2009, P = 0.002). The distribution of
sub-types of influenza A is reported in Table 1. In 2010
there were 283 patients with confirmed H1N1 2009
admitted to ICU, corresponding to a population inci-
dence of admission to ICU of 10.6 (95% CI, 9.4 to 11.9)
per million inhabitants [7,8]. By comparison, during
2009 there were almost three times as many patients
with confirmed H1N1 2009 (n = 921), corresponding to
a population incidence of admission to ICU of 35.2
(95% CI, 32.9 to 37.5) per million inhabitants [7,8] (P <
0.001). The geographical distribution of admissions was
also different between 2010 and 2009 (Table 1). In 2010
the population incidence in Australia was 2-fold lower
than in New Zealand (P < 0.001), whereas in 2009 this
relationship was reversed with a 1.3-fold higher inci-
dence in Australia (P = 0.009). The overall incidence,
combining 2009 and 2010, was 45.3 (95% CI, 42.4 to
48.2) admission to ICU per million inhabitants in Aus-
tralia and 47.1 (95% CI, 40.5 to 53.7) in New Zealand (P
= 0.65).
The number of patients admitted to an ICU with
H1N1 2009 according to study week is displayed in Fig-
ure 1. In 2010 the onset of the epidemic was delayed
(by five weeks) and the peak incidence was lower. The
impact on ICU services was significantly lower in 2010
with peak daily ICU bed occupancy being 7.5 (95% CI,
6.5 to 8.6) per million inhabitants in 2009 compared
with 2.4 (95% CI, 1.8 to 3.0) per million inhabitants in
2010 (P < 0.001) (Table 1).
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were broadly similar in 2010 to those admitted in 2009
(Table 2). Comparing 2010 with 2009 there were no
significant differences in the distribution of cases
among different age groups. In both study periods the
highest number of ICU admissions occurred among
patients aged between 25 and 49. There was no differ-
ence in the proportion of patients with a body mass
index greater than 35 kg/m
2, who were pregnant or
post-partum or who had no known predisposing factor
between that observed in 2009 and 2010 (Table 2).
The proportion of patients with asthma or chronic
obstructive pulmonary disease, chronic heart failure, or
an Acute Physiology Age Chronic Health Evaluation
(APACHE) III or paediatric co-existing illness was
lower in 2010, but these factors were still over-repre-
sented in comparison to the general population, as
they were in 2009 [3] (Table 2). Furthermore, a similar
spectrum of clinical illness was observed in 2010 as in
2009, with viral pneumonitis or the acute respiratory
distress syndrome (ARDS) being the most common
presentation. The severity of illness, as inferred from
the proportion of patients treated with mechanical
ventilation, renal replacement therapy and vasopressor
medications, was not different between the two study
periods. The durations of admission to ICU and to the
hospital were 8.5 (IQR = 3.2 to 16.1) days in 2010
compared with 7.0 (IQR = 3.0 to 16.0) days in 2009 (P
= 0.32), and 15.4 (IQR = 7.5 to 25.6) in 2010 compared
with 16.6 (IQR = 7.0 to 31.0) in 2009 (P =0 . 3 8 ) ,
respectively. In addition, in 2010, 13% of patients died
before hospital discharge. This proportion was not dif-
ferent to that observed in 2009, although follow up
was more complete for patients in 2009, with 45
patients (15.9%) from 2010 still being in hospital at
time of censoring compared with 63 patients (6.8%) in
2009.
A vaccine for H1N1 2009 was not available at any
time during the 2009 study period but became available
Table 1 Epidemiological characteristics of ICU admissions due to influenza A in 2010 and 2009 in Australia and New
Zealand
2010 2009 P-value
Number of Influenza A cases 315 1113
H1N1 2009 283 (90%) 921 (83%) 0.002
Seasonal H1N1 0 (0%) 36 (3%) < 0.001
Seasonal H3N2 3 (1%) 24 (2%) 0.17
Not sub-typed or other 29 (9%) 132 (12%) 0.22
Incidence of admission to ICU per million inhabitants, (95% CI)
ANZ 10.6 (9.4 to 11.9) 35.2 (32.9 to 37.5) < 0.001
Australia 9 (7.8 to 10.3) 36.5 (34 to 39.1) < 0.001
New Zealand 18.8 (14.6 to 23) 28.3 (23.2 to 33.5) 0.005
Maximum daily ICU occupancy per million inhabitants, (95% CI) 2.4 (1.8 to 3.0) 7.5 (6.5 to 8.6) < 0.001
ANZ, Australia and New Zealand; ICU, intensive care unit
Figure 1 Number ICU admission with H1N1 2009 according to study week during 2009 (white bars) and 2010 (dark bars).
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periods. Publically available data suggest that at least
4.86 million (21.8%) Australians [12] and 1.05 million
(24.1%) of New Zealanders (personal communication,
Jane Chambers, Ministry of Health) were vaccinated
against H1N1 2009 up to the end of June 2010. Of 170
patients admitted in 2010 for whom vaccination status
was known, 26 (15.3%) had been vaccinated against
H1N12009, of whom 16 were from Australia and 10
from New Zealand.
Discussion
We studied all patients with confirmed H1N1 2009
infection admitted to Australian and New Zealand ICUs
during the second winter of the epidemic in 2010 and
compared this experience with that which occurred dur-
ing the winter of 2009. We identified 283 patients with
confirmed H1N1 2009 infection, giving a population
incidence of 10.6 ICU admissions per million inhabi-
tants, a quarter of the incidence observed in 2009.
H1N1 2009 remained the dominant cause of ICU
Table 2 Characteristics of patients, clinical presentation and outcome of confirmed critical illness related to H1N1
2009 influenza in 2010 and 2009
2010 2009 P-value
Age, years
Median (IQR) 42 (28 to 53) 39.8 (27 to 53) 0.86
Age distribution, years no./total no. (%) 0.13
0 to < 1 8/271 (3%) 34/921 (4%) 0.45
1 to 4 12/271 (4%) 21/921 (2%) 0.1
5 to 24 31/271 (11%) 128/921 (14%) 0.21
25 to 49 128/271 (47%) 415/921 (45%) 0.92
50 to 64 87/271 (32%) 242/921 (26%) 0.13
> 65 16/271 (6%) 79/921 (9%) 0.11
Female sex, no./total no. (%) 134/283 (47%) 498/921 (54%) 0.048
Pregnant or post-partum women, 29/283(10.2%) 81/921 (8.8%) 0.54
Ethnicity, no./total no. (%)
Caucasian 212/280 (75.7%) 633/887 (71.4%) 0.16
Aboriginal or Torres Strait Islander admitted to ICU in Australia 9/199 (4.5%) 82/765 (10.7%) 0.01
Maori admitted to ICU in New Zealand 16/81 (19.8%) 34/122 (27.9%) 0.25
Pacific Islander 13/280 (4.6%) 43/887 (4.8%) 0.89
Asian 13/280 (4.6%) 39/887 (4.4%) 0.86
Other 17/280 (6%) 56/887 (6.3%) 0.88
Adults with BMI > 35, no./total no. (%) 60/215 (27.9%) 177/642 (27.6%) 0.96
Diabetes, no./total no. (%) 42/277 (15%) 148/900 (16%) 0.61
Asthma or chronic obstructive pulmonary disease, no./total no. (%) 73/278(26%) 297/915 (32.5%) 0.05
Chronic heart failure, no./total no. (%) 14/277 (5%) 99/910 (10.9%) 0.004
APACHE III or pediatric co-morbidity, no./total no. (%) 52/279 (19%) 251/891 (28.2%) 0.002
No known predisposing factors, no./total no. (%) 107/283 (38%) 300/921 (33%) 0.1
Influenza syndrome < 0.001
Viral pneumonitis or ARDS, no./total no. (%) 147/255 (58%) 438/896 (48.9%) 0.014
Secondary bacterial pneumonia, no./total no. (%) 71/255 (28%) 177/896 (19.6%) 0.006
Exacerbation of airflow limitation, no./total no. (%) 20/255 (8%) 120/896 (13.4%) 0.017
Inter-current illness or other, no./total no. (%) 17/255 (6.7%) 161/896 (18%) 0.001
Duration of treatment in ICU, days
Median (IQR)
8.5 (3.2 to 16.1) 7 (3.0 to 16) 0.32
Duration of treatment in hospital, days
Median (IQR)
15.4 (7.5 to 25.6) 16.6 (7.0 to 31.0) 0.38
Patients treated with MV, no./total no. (%) 186/282 (66%) 579/909 (63.7%) 0.53
Patients treated with vasopressor drugs, no./total no. (%) 104/269 (39%) 276/787 (35%) 0.29
Patients treated with renal replacement therapy, no./total no. (%) 20/275 (7.3%) 50/800 (6.3%) 0.65
Patients treated with ECMO, no./total no. (%) 12/278 (4.3%) 57/579 (9.8%) 0.008
Mortality, no./total no. (%) 32/238 (13%) 136/858 (15.9%) 0.42
ARDS, acute respiratory distress syndrome; APACHE III, Acute Physiology Age Chronic Health Evaluation III; BMI, body mass index; ECMO, extra corporeal
membrane oxygenation; ICU, intensive care unit; MV, mechanical ventilation
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[3]. The second wave occurred later in the year but
resulted in similar illness severity, affected similar
groups at risk and caused similar in-hospital mortality.
The incidence of H1N1 2009 influenza critical illness
during 2010 was higher in NZ than in Australia, which
was a reversal of the pattern in 2009. However, the
combined incidence over both winters was similar in
both countries. We observed vaccination failure in a
substantial proportion of patients for whom vaccination
status was known. Our observations do not support the
view that the H1N1 2009 pandemic has come to an end
[13].
Although the incidence of critical illness was signifi-
cantly lower in 2010 the pattern of illness among
patients who were admitted to an ICU was similar to
that observed in 2009 and in other reports of patients
admitted to ICUs [14-16]. ARDS was present in more
than 50% of patients, as previously described in ANZ [3]
and worldwide [14,15,17-21]. The length of stay in ICU
was unchanged [3] and similar to that reported else-
where [14,20]. The risk factors for admission to ICU
were similar to those reported during the first wave
[3,22,23]. In addition, the treatments administered and
the mortality that occurred were similar to that
observed in 2009 in ANZ as well as elsewhere
[3,13,14,18].
The incidence of ICU admission per million inhabi-
tants was higher in Australia than in New Zealand in
2009 (36.5 versus 28.3 admissions to ICU per million
inhabitants) [3]. Conversely, in 2010 this incidence was
higher in New Zealand. This difference is concordant
with national data reporting 6,064 confirmed H1N1
cases in Australia (272 cases per million inhabitants)
versus 1,810 in New Zealand (415 cases per million
inhabitants in 2010) during the same period [2,24]. The
proportion of confirmed cases hospitalised (727 of 1,810
= 40.1%) [25], and of hospitalised cases admitted to ICU
(82 of 732 = 11.2%) in New Zealand was similar to 2009
[26]. Accordingly, the higher ICU admission rate per
population observed in 2010 was due to a higher inci-
dence of community infection, rather than a difference
in severity of disease. The reason for the difference in
infection rate between Australia and New Zealand in
2010 is unclear, as a similar proportion of the popula-
tion was seropositive after the 2009 pandemic wave in
Australia (22% (95% CI 19.1 to 24.9)) compared to New
Zealand (26.7% (95% CI 22.6 to 29.4)) [27,28] and a
similar proportion were vaccinated (21.8% versus 24.1%,
respectively) during the inter-wave period. Possible
explanations include natural variations in community
spread of influenza or an effect of the difference in vac-
cination deployment where Australia used both early
monovalent and later polyvalent vaccines while New
Zealand relied predominantly on delivery of the polyva-
lent vaccine alone, although overall coverage was
similar.
We found that 15.3% of those patients for whom data
were available had been previously vaccinated, which is
consistent with another report of H1N1 2009 vaccina-
tion effectiveness [29]. In a critically ill patient with a
severe pneumonia and a history of H1N1 vaccination
the possibility of vaccination failure and H1N1 2009
infection should be considered.
Our data are subject to some limitations. To make
this report available in a timely manner, we censored
hospital outcome data. Ascertainment of cases of H1N1
2009 admitted to ICUs in 2010 as well as in 2009 may
not have been complete, and we cannot exclude the
possibility that a small number of cases were not
reported to the registry, and false negative diagnostic
tests may well have underestimated the true burden of
H1N1 2009 in our patients. Among the patients with
confirmed influenza A, there were 29 in whom the
influenza was not sub-typed in 2010 and 132 in 2009.
Thresholds for undertaking testing both in hospital and
in the community were not standardised. It is not possi-
ble to reach a conclusion regarding the efficacy of vacci-
nation as the vaccination status of many patients was
unknown. Finally, while we report a similar severity of
the illness to 2009, we do not have information about
anti-viral treatment, potential viral mutation and resis-
tance to anti-viral drugs. Finally, we did not evaluate the
role played by a corticosteroid therapy on the outcome
of patients with ARDS, and we were not able to cope
with the controversy about the effect of this treatment
[30].
Conclusions
In conclusion, the impact of the second H1N1 2009
winter epidemic was still substantial although signifi-
cantly less than in 2009. It had a lower peak occurring
approximately five weeks later than in 2009, affected
similar individuals, was similar in clinical severity, car-
ried a similar mortality rate. In patients with H1N1
2009 infection requiring ICU admission a number of
apparent vaccination failures were observed. Based on
these data and despite the deployment of the vaccina-
tion, a second season of H1N1 2009 influenza may still
have a substantial intensive care impact.
Key messages
￿ H1N1 (2009) had a substantial impact on ICU
resources during the winter of 2010 in Australia and
New Zealand.
￿ Risk factors remain similar to those reported in
2009 and include obesity, pregnancy and presence of
comorbidity.
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with mechanical ventilation, renal replacement ther-
apy, vasopressor drug, and extracorporeal membrane
oxygenation as well as by hospital mortality, was
similar to that observed the previous year.
￿ Vaccination against H1N1 (2009) doesn’te x c l u d e
the possibility of developing critical illness due to
infection with H1N1 (2009) flu.
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